Beyond the Depot: Rethinking RTSM for Cell & Gene Therapy Success 

By Monique Muller, MSc, Senior Project Director, Global Project Leadership at Allucent

The rise of cell and gene therapies (CGT) is one of the most exciting chapters in modern medicine. These breakthroughs are rewriting the rules of what’s possible for patients with cancer, autoimmune conditions, and rare diseases. But as science pushes boundaries, clinical operations are being tested in ways traditional systems were never designed to handle. 

For biotech sponsors, this is a pivotal moment. Success in CGT trials isn’t just about innovation in the lab, it’s about building the operational backbone that ensures every patient receives the right therapy, in the right condition, at exactly the right time. And the key to that backbone? Rethinking how we approach Randomization and Trial Supply Management (RTSM). 

Why Traditional Randomization and Trial Supply Management No Longer Works

In conventional drug development, RTSM focuses on predictable supply flows: depot → site → patient. Inventory is standardized, interchangeable, and relatively linear. 

But in CGT trials, especially autologous therapies where the patient is both donor and recipient, none of these assumptions hold true (Figure 1). Each product is unique, made-to-order, and tied to a compressed “vein-to-vein” timeline. The patient themselves becomes part of the supply chain (Figure 2). Even allogeneic therapies, with their donor-derived batch models, face individualized distribution challenges that stretch beyond standard Randomization and Trial Supply Management capabilities. 

For project managers and clinical operations leaders, the risks are clear: manual spreadsheets, email chains, and disconnected tools simply cannot provide the precision, compliance, or agility these trials demand. 

The Three Chains Every Sponsor Must Master

At the heart of CGT logistics there are three non-negotiable chains – identity, condition, and custody. These interconnected controls are what ensure that every personalized therapy moves safely, compliantly, and efficiently from collection to administration. Each chain serves a distinct but complementary role in protecting patient safety and product integrity: 

• Chain of Identity: A failure here could mean delivering the wrong product to a patient which is a catastrophic risk to safety and trial integrity. 

• Chain of Condition: Living therapies are highly sensitive; even minor temperature excursions can compromise viability. Real-time monitoring is essential. 

• Chain of Custody: Every handoff must be documented with full traceability, ensuring accountability across borders, stakeholders, and time zones. 

Any break in these chains puts not just the study, but the patient, at immediate risk. 

Patient-Centric Randomization and Trial Supply Management for a Patient-Centric Therapy

Biotech companies that want to lead in CGT need to move beyond inventory tracking and embrace a central command hub for individualized clinical supply. The most effective systems today share five critical attributes: 

1. Patient-centricity: Full vein-to-vein visibility, built to handle individualized therapies. 

2. Real-time responsiveness: Dynamic updates that keep pace with shifting manufacturing slots, patient availability, and logistical delays. 

3. Integrated operations: Seamless data flow between sites, manufacturers, and couriers with proactive shipment alerts. 

4. Regulatory rigor: Audit trails and compliance guardrails built in from day one. 

5. Scalability: Flexibility to handle small cohorts now and expanded hybrid or mixed-modality trials later. 

The Allucent + Veeva RTSM Advantage 

Recognizing the growing complexity of cell and gene therapy logistics, where every patient represents a unique product, every timeline is compressed, and every shipment carries critical regulatory and safety implications, Allucent and Veeva joined forces to rethink how Randomization and Trial Supply Management should function in this environment. 

Traditional systems were designed for linear, predictable supply chains: depot to site to patient. But in CGT trials, those assumptions break down. Manual data capture and siloed communication between sites, labs, couriers, and manufacturers introduce unacceptable risks, missed manufacturing slots, temperature excursions, lost documentation, and, ultimately, threats to patient safety and trial integrity. 

The Allucent + Veeva collaboration addresses these challenges head-on with a next-generation RTSM solution purpose-built for patient-centric, highly individualized studies. The system is designed to reduce risk, accelerate timelines, and support both small biotech innovators and larger sponsors managing complex pipelines. 

Key differentiators include: 

• Flexible study-specific configurations: Tailored to your protocol, without costly custom builds. 

• Temperature and logistics integration: Real-time excursion management and alerts to protect living therapies. 

• Streamlined setup: Faster go-live and lower operational burden, critical in early-phase trials where every week matters. 

• Familiar interfaces: Reducing site burden and driving adoption among stakeholders. 

From foundational systems integration to enhanced patient outcomes, the Allucent + Veeva RTSM model delivers scalable, compliant, and real-time coordination. By leveraging an existing infrastructure, this solution minimizes cost while providing the adaptability needed to grow with your portfolio. 

Why This Matters Now 

CGT programs are moving at breakneck speed, but the cost of getting logistics wrong is unforgiving: product loss, treatment delays, and worst of all, patient safety risks. For biotech companies seeking to prove value, attract investment, or accelerate to commercialization, operational excellence in Randomization and Trial Supply Management is no longer optional. It’s a strategic differentiator. 

By embracing patient-centric RTSM systems built for the realities of CGT, biotech companies can not only de-risk their trials but also position themselves as leaders in bringing transformative therapies to patients faster. 

In cell and gene therapy, every detail matters. The sponsors who master RTSM today will be the ones shaping the standard of care tomorrow.